GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Plandai Biotechnology Inc (OTCPK:PLPL) » Definitions » Peter Lynch Fair Value

Plandai Biotechnology (Plandai Biotechnology) Peter Lynch Fair Value : N/A (As of Jun. 10, 2024)


View and export this data going back to . Start your Free Trial

What is Plandai Biotechnology Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Plandai Biotechnology's Peter Lynch Fair Value or its related term are showing as below:



PLPL's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.74
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Plandai Biotechnology Peter Lynch Fair Value Historical Data

The historical data trend for Plandai Biotechnology's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plandai Biotechnology Peter Lynch Fair Value Chart

Plandai Biotechnology Annual Data
Trend Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Plandai Biotechnology Semi-Annual Data
Mar03 Mar04 Mar05 Mar06 Mar07 Mar08 Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Plandai Biotechnology's Peter Lynch Fair Value

For the Shell Companies subindustry, Plandai Biotechnology's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Plandai Biotechnology's Price-to-Peter-Lynch-Fair-Value Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Plandai Biotechnology's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Plandai Biotechnology's Price-to-Peter-Lynch-Fair-Value falls into.



Plandai Biotechnology Peter Lynch Fair Value Calculation

Plandai Biotechnology's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-0
=N/A

For company reported annually, GuruFocus uses latest annual data as the TTM data. Plandai Biotechnology's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Plandai Biotechnology  (OTCPK:PLPL) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Plandai Biotechnology's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.0004/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Plandai Biotechnology Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Plandai Biotechnology's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Plandai Biotechnology (Plandai Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
4811 49th Street, San Diego, CA, USA, 92115
Plandai Biotechnology Inc. manufactures highly bioavailable extracts from live plant materials.
Executives
Callum Baylis-duffield director FLAT 37 ISLAND HOUSE THREE MILL LANE, LONDON ENGLAND X0 E33AF
Timothy Matula other: Former Director 175 JACKSON AVE N, SUITE 102, MINNEAPOLIS MN 55343
Brian Johnson director P.O. BOX 1594, FERNDALE WA 98248-1594
Roger Duffield director, officer: President, Secretary and CFO 2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
Daron Baylis Duffield director 2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
David Rzepnicki director 21 HORIZON DRIVE, SARATOGA SPRINGS NY 12866